Administration Supplies as Intended-Use Evidence: The March 2026 Letters
Updated August 21, 2026
The FDA warning letters of March 31, 2026 cite administration supplies offered in the same shopping cart as research peptides as evidence that the peptides were intended for human use. The finding is structural: the letters count the composition of the checkout, not any written claim, as part of the intended-use record.
The finding
Across the seven-letter batch, two categories of evidence recur. One is descriptive — product-page language characterizing what a compound does in a person. The other is the subject of this page: sellers offered supplies for administering the compounds in the same cart as the compounds themselves. Per the letters, that pairing entered the record as evidence of intended use. A buyer assembling a research shipment has no need for the second item; a buyer assembling something else does. The letters draw that inference and say so.
Which letters carry the finding
The verified record this index draws on documents the finding at the batch level. FDA's stated focus for the March 31, 2026 action, per the letters and contemporaneous coverage, was therapeutic-effect descriptions plus administration supplies in the same cart. A per-letter breakdown — which of the seven checkouts carried which supplies — is not in the verified record, and this index does not attribute the finding to individual recipients beyond what the batch-level record supports. The seven entities, their letter numbers, and their locations are tabulated in the batch record.
| Batch | Seven letters, dated March 31, 2026, posted April 7, 2026 |
|---|---|
| Finding | Administration supplies offered in the same cart as the compounds |
| Attribution level | Batch — per-letter detail not captured in the verified record |
| Companion finding | Therapeutic-effect descriptions on product pages |
Why cart composition counts
The reasoning follows from the position the same letters state about disclaimers: despite research-use labels, "evidence obtained from your website establishes that your products are intended to be drugs for human use." Intended use, on that reading, is assembled from everything the seller publishes — and a checkout is published. What a store offers beside a compound communicates a use for it as plainly as a sentence would, without a sentence a compliance review could flag. The March 2026 letters close that gap. The cart itself is the exhibit.
This was the batch's extension of the method. The December 2024 letters built their intended-use cases from written material — listings and a social-media post. Fifteen months later the same analysis reached store structure. The disclaimer question that runs through both batches has its own page: research-use-only disclaimers in the warning-letter record.
What the record does not show
The letters do not state that selling such supplies is itself a violation, and this index makes no claim about supply items sold alone. The documented finding concerns pairing: compound and administration supplies in one cart, weighed together with the rest of the site as evidence of what the compound was for. Sellers' responses to the seven letters, if any were made public, are likewise not in the verified record here.
All seven recipients are catalogued in the Vendor Closure and Enforcement Index.
Sources
- FDA Warning Letter, Lovega LLC dba Pink Pony Peptides, 721088-03312026. fda.gov
- FDA Warning Letter, Mile High Compounds LLC, 721600-03312026. fda.gov
- FDA Warning Letter, Gram Peptides, 721806-03312026. fda.gov
- FDA Warning Letters database (remaining letters of the batch). fda.gov
- Policy Canary analysis of the batch. policycanary.io
- Partnership for Safe Medicines, summary of the seven letters (posted April 7, 2026). safemedicines.org
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.